Research progress in the preoperative radiotherapy and immunotherapy for primary liver cancer
10.3760/cma.j.cn112271-20211102-00439
- VernacularTitle:原发性肝癌术前放疗及免疫治疗的研究进展
- Author:
Wenhui LIU
1
;
Xiaolian ZHENG
;
Cairong HU
;
Hongbing JI
;
Jianji PAN
;
Juhui CHEN
Author Information
1. 福建医科大学孟超肝胆医院放疗科，福州 350025
- Keywords:
Primary liver cancer;
Preoperative radiotherapy;
Neoadjuvant therapy;
Immunotherapy
- From:
Chinese Journal of Radiological Medicine and Protection
2022;42(3):235-240
- CountryChina
- Language:Chinese
-
Abstract:
Liver cancer is one of the most common cancers in China. In recent years, liver cancer tends to be treated with comprehensive therapies, including surgery, ablation, interventional embolization, radiotherapy, chemotherapy, targeted therapy, immunotherapy, and liver transplantation. At present, the low surgical resectionrate is one of the main factors affecting the prognosis of liver cancer patients. Preoperative neoadjuvant therapy or conversion therapy for liver cancer can maximize the rate of surgical resection and improve the prognosis. With the rapid development of radiotherapy and immunotherapy in the comprehensive treatment of liver cancer, it has been gradually confirmed that the unique effects of preoperative radiotherapy and immune therapy for liver cancer can improve the prognosis of the patients. Therefore, this paper reviewed the research progress in the preoperative radiotherapy and immunotherapy for liver cancer by searching relevant literature and reports at home and abroad.
